Canadian government awards US$493,000 to Medicago

Published: 11-Dec-2012
Research & Development Finance Pharmaceutical

To support development of new potency assays and process analytical technologies


Medicago, a Canadian biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), has been awarded up to US$493,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

The investment will support the development of new potency assays and process analytical technologies for Medicago's pandemic and seasonal influenza VLP vaccine candidates.

‘The development of the best assays that can ensure rapid release and availability of our influenza vaccine candidates aligns well with our strategy to deliver highly effective vaccines in the quickest possible manner,’ said Andy Sheldon, president and CEO of Medicago.

‘This contribution continues to demonstrate our long-standing relationship with NRC IRAP. We would sincerely like to thank them for their continued support and encouragement of Medicago.’

Medicago will work with NRC teams in Montreal and Ottawa to establish assays for more rapid lot release and better in-process control.

  • Companies:
  • Medicago
See more

You may also like

Design & Build

Medicago contributes CA$500,000 to help establish Class 3 containment laboratory at Université Laval

Read more
Remaining two-thirds of the funds will be provided by the City of Quebec and the research centre's foundation

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  3. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  4. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  5. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Design & Build

Medicago contributes CA$500,000 to help establish Class 3 containment laboratory at Université Laval

Remaining two-thirds of the funds will be provided by the City of Quebec and the research centre's foundation
Research & Development

Medicago to develop Ebola monoclonal antibodies for the Canadian government

Plant-based antibodies to be developed in mini-factories to fight the Sudan strain of the Ebola virus
Manufacturing

Medicago to build C$245m vaccine production facility in Quebec City, Canada

Will create 200 new highly skilled jobs by 2019
Finance

Mitsubishi Tanabe Pharma to acquire Medicago for $357m

Medicago has been collaborating with MTPC since 2012 to develop and commercialise rotavirus VLP-based vaccines
Manufacturing

Medicago produces rotavirus VLP vaccine candidate

It comprises all four structural antigens of rotavirus using its plant-based manufacturing platform
Research & Development

Medicago and Mitsubishi to develop next generation technology for plant production

Companies to evaluate closed hydroponic Plant Factory System
Research & Development

Medicago and Philip Morris sign influenza vaccines agreement for China

Medicago to receive up to US$12m in royalties
Subscribe now